Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment

被引:22
作者
Kawamura, N
Ito, F
Ichimura, T
Shibata, S
Umesaki, N
Ogita, S
机构
[1] Department of Obstetrics, Osaka City University Medical School, Osaka
[2] Department of Obstetrics, Osaka City University Medical School, Osaka 545, 1-5-7 Asahimachi, Abeno-ku
基金
美国国家卫生研究院;
关键词
uterine leiomyoma; needle biopsy; gonadotropin-releasing hormone agonist;
D O I
10.1016/S0015-0282(97)00273-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To analyze histopathologic features related to myoma volume reduction after treatment with a GnRH agonist, buserelin acetate, in needle biopsy specimens obtained before treatment. Design: Prospective clinical study. Setting: University teaching hospital. Patient(s): Twenty women with normal menstrual cycles and symptomatic uterine myomas. Intervention(s): Buserelin acetate was administered intranasally (900 mu g/d) for at least 16 weeks; transcervical needle biopsy of the uterine myoma was done before this treatment. Main Outcome Measure(s): The relation between histopathologic features (degree of cellularity, hyaline change, and collagen content) and the percent decrease in the volume of the largest myoma at 16 weeks measured by magnetic resonance imaging. Result(s): The correlation between the degree of hyaline change and the percent decrease in the myoma volume was significant, as was that with the proportion of collagenous tissue in the specimens. Conclusion(s): We predicted myoma volume reduction after treatment with a GnRH agonist by histologic analysis of the uterine leiomyoma before treatment. (C) 1997 by American Society for Reproductive Medicine.
引用
收藏
页码:632 / 636
页数:5
相关论文
共 22 条
[1]  
ADAMSON GD, 1992, AM J OBSTET GYNECOL, V166, P746
[2]  
BARBIERI RL, 1993, FERTIL STERIL, V60, P569
[3]  
COHEN D, 1994, J REPROD MED, V39, P377
[4]   THE HISTOPATHOLOGY OF UTERINE LEIOMYOMAS FOLLOWING TREATMENT WITH GONADOTROPIN-RELEASING-HORMONE ANALOGS [J].
COLGAN, TJ ;
PENDERGAST, S ;
LEBLANC, M .
HUMAN PATHOLOGY, 1993, 24 (10) :1073-1077
[5]   MORPHOLOGICAL-CHANGES IN UTERINE LEIOMYOMAS TREATED BY GNRH AGONIST GOSERELIN [J].
CROW, J ;
GARDNER, RL ;
MCSWEENEY, G ;
SHAW, RW .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (03) :235-242
[6]   Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata [J].
Deligdisch, L ;
Hirschmann, S ;
Altchek, A .
FERTILITY AND STERILITY, 1997, 67 (05) :837-841
[7]  
FRIEDMAN AJ, 1992, FERTIL STERIL, V58, P413
[8]  
GUTMANN JN, 1994, FERTIL STERIL, V61, P622
[9]   IMMUNOHISTOCHEMICAL ANALYSIS OF ESTROGEN-RECEPTORS, PROGESTERONE RECEPTORS AND KI-67 IN LEIOMYOMA AND MYOMETRIUM DURING THE MENSTRUAL-CYCLE AND PREGNANCY [J].
KAWAGUCHI, K ;
FUJII, S ;
KONISHI, I ;
IWAI, T ;
NABU, Y ;
NONOGAKI, H ;
ISHIKAWA, Y ;
MORI, T .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1991, 419 (04) :309-315
[10]  
KAWAMURA N, 1996, J GYNECOL TECH, V2, P201